NeoTract

NeoTract was a privately-held medical device company headquartered in Pleasanton, California, focused on addressing unmet needs in urology. Founded in 2004 by Ted Lamson and Joseph Catanese, the company developed and commercialized the FDA-cleared UroLift System — a minimally invasive permanent implant that treats lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH) while preserving sexual function. The UroLift System became a widely adopted alternative to medications and major surgery for enlarged prostate. NeoTract was acquired by Teleflex in October 2017 for up to $1.1 billion ($725M upfront plus up to $375M in milestone payments).